The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome
Abstract
Aims: Triple‐negative breast cancer (TNBC) patients generally have a poor outcome; there is a pressing need to identify more effective therapeutic strategies. Clinical trials targeting programmed death 1/programmed death ligand 1 (PD 1/PDL 1) in melanoma and non‐small‐cell lung cancer have reported high response rates, and tumoral PDL 1 expression has been suggested as a potential biomarker to enrich for patient response to these treatments. There are only very limited data to date reporting the expression of PDL 1 in TNBC. Methods and results: PDL 1 immunohistochemistry was performed on 161 primary TNBC s and assessed in the tumour as well as immune cells in the stromal compartment. PDL 1 expression was very common in TNBC, expressed in the tumour cell membrane (64%), cytoplasm (80%) and stromal (93%) cellular compartments. Cytoplasmic tumoral expression of PDL 1 was associated with a lower risk of breast cancer‐specific death [hazard ratio (HR) 0.45, P = 0.035] while stromal PDL 1 expression was associated with a lower rate of deaths from all causes (HR 0.305, P = 0.0042). Membranous expression of PDL 1 was not associated with outcome. While both PDL 1 expression and tumour‐infiltrating lymphocytes were associated with a better outcome, only lymphovascular invasion and high tumour‐infiltrating lymphocytes were independently prognostic for breast cancer‐specific death. Conclusion: While PDL 1 expression is frequent in TNBC, it was not independently prognostic. There were differences in outcome depending on the cellular compartment of PDL 1 expression. These data provide further impetus for investigating the utility of immune checkpoint therapies in TNBC, given the clinical significance of tumour‐infiltrating lymphocytes (TIL s) and PDL 1 expression in this cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Data in clinical trials of PD1/PDL1 inhibitors in melanoma and NSCLC have suggested that the expression of PDL1 is associated with a higher response rate,(6) and recent clinical trials utilizing PD1/PDL1 antibodies in melanoma, NSCLC and renal cell carcinoma have shown safety and durable tumour regression.(7) Early da…”
ResultPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Cited by
Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.072 · Cited by 413
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Humby, F., Durez, P., Buch, M. H., Lewis, M. J., Rizvi, H., Rivellese, F., Nerviani, A., Giorli, G., Mahto, A., Montecucco, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32341-2 · Cited by 329
Metadata
- Authors
- Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K., Holliday, A., Cooper, C. L., Robbins, E., Gillett, D., Kennedy, C. W., Gluch, L., Carmalt, H., Mak, C., Warrier, S., Gee, H. E., Chan, C., McLean, A., Walker, E., McNeil, C. M., Beith, J. M., Swarbrick, A., Scolyer, R. A., & O'Toole, S. A.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2016-01-13
- Volume
- 69
- Issue
- 1
- Pages
- 25-34
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2277555391
- Cited by
- 231
- References
- 3
- FWCI
- 6.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome. https://app.cochat.ai/papers/10.1111/his.12904
- The paper
- Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K., Holliday, A., Cooper, C. L., Robbins, E., Gillett, D., Kennedy, C. W., Gluch, L., Carmalt, H., Mak, C., Warrier, S., Gee, H. E., Chan, C., McLean, A., Walker, E., . . . O'Toole, S. A. (2016). Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome. Histopathology. https://doi.org/10.1111/his.12904
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.